Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, GA.
Navajo Area, Indian Health Service, Chinle, AZ.
Sex Transm Dis. 2024 Dec 1;51(12):794-802. doi: 10.1097/OLQ.0000000000002064. Epub 2024 Aug 10.
National case rates of chlamydia and gonorrhea (CT/GC) among American Indian and Alaska Native (AI/AN) persons are disproportionately high. The Indian Health Service (IHS), which provides health care to members of federally recognized tribes, does not currently have a dedicated CT/GC surveillance system. The purpose of this study was to validate the use of CT/GC diagnostic codes for estimating diagnosed CT/GC infections among AI/AN persons who use IHS services.
We conducted a retrospective study using IHS medical records from all persons 15 years and older from 2016 to 2021. We linked records with CT (A56, A74) and GC (A54, O98.2) International Classification of Diseases, 10th Revision, Clinical Modification diagnostic codes to laboratory results within 30 days for each person. We calculated the sensitivity, specificity, and positive and negative predictive values of CT/GC diagnostic codes using laboratory test results as the reference standard.
We identified more than 1.6 million CT/GC laboratory tests, and 52,815 CT and 19,971 GC diagnostic codes. Diagnostic code sensitivity was slightly higher for CT (54%) than GC (50%). Specificity, positive predictive value, and negative predictive value were high for CT and GC (range, 83.3%-99.8%). About one-third of CT/GC diagnostic codes could not be linked to a test result.
The validation indicates that diagnostic codes align well with linked laboratory test results. However, because of the relatively large number of diagnostic codes and positive test results that could not be linked, combining the 2 would inform more reliable estimates of diagnosed CT/GC infections among AI/AN persons who use IHS for health care.
美国印第安人和阿拉斯加原住民(AI/AN)人群中的衣原体和淋病(CT/GC)全国发病率高得不成比例。为联邦认可的部落成员提供医疗服务的印第安卫生服务(IHS)目前没有专门的 CT/GC 监测系统。本研究的目的是验证使用 CT/GC 诊断代码来估计使用 IHS 服务的 AI/AN 人群中诊断出的 CT/GC 感染。
我们进行了一项回顾性研究,使用了 2016 年至 2021 年期间所有 15 岁及以上的 IHS 医疗记录。我们将记录与 CT(A56、A74)和 GC(A54、O98.2)国际疾病分类,第 10 次修订版,临床修正诊断代码与每个人 30 天内的实验室结果相关联。我们使用实验室检测结果作为参考标准,计算了 CT/GC 诊断代码的灵敏度、特异性、阳性和阴性预测值。
我们确定了超过 160 万例 CT/GC 实验室检测,52815 例 CT 和 19971 例 GC 诊断代码。诊断代码的敏感性略高于 CT(54%)比 GC(50%)。CT 和 GC 的特异性、阳性预测值和阴性预测值都很高(范围,83.3%-99.8%)。大约三分之一的 CT/GC 诊断代码无法与检测结果相关联。
验证表明诊断代码与相关联的实验室检测结果吻合良好。然而,由于大量的诊断代码和无法关联的阳性检测结果,将这两者结合起来,可以为使用 IHS 进行医疗保健的 AI/AN 人群中诊断出的 CT/GC 感染提供更可靠的估计。